Provided by Tiger Trade Technology Pte. Ltd.

Greenwich Lifesciences Inc

16.67
+1.368.88%
Post-market: 16.63-0.0420-0.25%19:56 EDT
Volume:176.79K
Turnover:2.96M
Market Cap:244.69M
PE:-10.56
High:17.48
Open:16.16
Low:15.54
Close:15.31
52wk High:34.10
52wk Low:7.78
Shares:14.68M
Float Shares:7.65M
Volume Ratio:1.46
T/O Rate:2.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5783
EPS(LYR):-1.4302
ROE:-986.32%
ROA:-235.98%
PB:78.50
PE(LYR):-11.66

Loading ...

Greenwich Lifesciences - Flamingo-01 Dsmb Recommends Study Continue Without Modification in May 2026

THOMSON REUTERS
·
Jul 20

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

GlobeNewswire
·
Jul 20

Greenwich LifeSciences Says EU Regulator Approves Combination of HLA Patients in Phase 3 Trial

MT Newswires Live
·
Jul 16

Greenwich Lifesciences Wins EMA Clearance to Combine HLA Patient Groups in Flamingo-01 Trial

Reuters
·
Jul 16

Greenwich Lifesciences Announces European Approval for Combining Both Hla Populations in Flamingo-01

THOMSON REUTERS
·
Jul 16

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

GlobeNewswire
·
Jul 16

U.S. Stocks on the Move-natera, Nlight, Micron

Reuters
·
Jul 10

U.S. Stocks on the Move-levi, Ionis Pharmaceuticals, Gloo Holdings

Reuters
·
Jul 09

Greenwich Lifesciences Rises After EMA Update for Breast Cancer Drug

Reuters
·
Jul 09

Greenwich Lifesciences Announces European Approval for Use of Commercially Manufactured Gp2 in Flamingo-01

THOMSON REUTERS
·
Jul 09

Greenwich Lifesciences - Seeks Approval to Use Gp2 Lot in UK and Canada

THOMSON REUTERS
·
Jul 09

EMA Clears Greenwich Lifesciences’ Commercially Manufactured GP2 for Use in Flamingo-01 Trial in Europe

Reuters
·
Jul 09

Greenwich Lifesciences Q1 net loss more than doubled to $5.66 million; R&D expenses rise 129% to $5.21 million

Reuters
·
Jun 04

Noble Financial Reaffirms Their Buy Rating on Greenwich LifeSciences (GLSI)

TIPRANKS
·
Jun 02

Greenwich LifeSciences Q4 EPS $(0.58) Misses $(0.31) Estimate

Benzinga Earnings
·
Jun 02

Greenwich Lifesciences FY25 net loss widens 11% to $19.36 million

Reuters
·
Jun 02

Greenwich LifeSciences presents FLAMINGO-01 data at ASCO

TIPRANKS
·
Jun 01

Greenwich LifeSciences reports higher immune response rates in GLSI-100 Phase III FLAMINGO-01 open-label arm data at ASCO 2026

Reuters
·
Jun 01

Greenwich Lifesciences Presents Flamingo-01 Phase Iii Trial Open Label Data Published at Asco Meeting 2026

THOMSON REUTERS
·
Jun 01

Greenwich LifeSciences Says Audit of 2025 Form 10-K Filing in Final Stages of Approval

MT Newswires Live
·
Jun 01